SecurityARLZ / Aralez Pharmaceuticals Inc.
InstitutionDeutsche Bank Ag\
Shares281,545
Value $ 97,000

Deutsche Bank Ag\ ownership in ARLZ / Aralez Pharmaceuticals Inc.

August 14, 2018 - Deutsche Bank Ag\ has filed a 13F-HR form disclosing ownership of 281,545 shares of Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) with total holdings valued at $97,000 USD as of June 30, 2018. Deutsche Bank Ag\ had filed a previous 13F-HR on May 15, 2018 disclosing 281,545 shares of Aralez Pharmaceuticals Inc. at a value of $421,000 USD. This represents a change in shares of 0.00 percent and a change in value of -76.96 percent during the quarter.

Other investors with positions similar to Deutsche Bank Ag\ include Par Capital Management Inc, Renaissance Technologies LLC, Salzhauer Michael, R&F Capital Advisors LP, Wells Fargo & Company/mn, and Macquarie Group Ltd.

Aralez Pharmaceuticals Inc. has declared a standard industrial code (sic) of 2834 which is the "Pharmaceutical Preparations" industry. Deutsche Bank Ag\'s top industries are "Fishing hunting and trapping" (sic 09), "Forestry" (sic 08), and "Legal Services" (sic 81).

13F Filings

The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.

In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Effective
Date
Form Security Class CUSIP Share
Price
Shares Change
(%)
Value
(x1000)
Change
(%)
Cost
(x1000)
Profit
(x1000)
Return
(%)
2018-06-30 13F-HR ARALEZ PHARMACEUTICALS COM 03852X100 0.92 281,545 0.00 97 -76.96 0 -324 -76.96
2018-03-31 13F-HR ARALEZ PHARMACEUTICALS COM 03852X100 1.46 281,545 -23.96 421 -19.66 -129 26 4.98
2017-12-31 13F-HR ARALEZ PHARMACEUTICALS COM 03852X100 1.85 370,245 -42.58 524 -64.50 -508 -444 -30.05
2017-09-30 13F-HR ARALEZ PHARMACEUTICALS COM 03852X100 1.82 644,760 -8.57 1,476 55.21 -110 635 66.77
2017-06-30 13F-HR ARALEZ PHARMACEUTICALS COM 03852X100 1.74 705,207 47.48 951 -6.95 396 -467 -45.66
2017-03-31 13F-HR ARALEZ PHARMACEUTICALS COM 03852X100 3.27 478,180 69.16 1,022 -17.98 640 -864 -69.32
2016-12-31 13F-HR ARALEZ PHARMACEUTICALS COM 03852X100 4.63 282,681 -4.93 1,246 -13.53 -68 -127 -8.83
2016-09-30 13F-HR ARALEZ PHARMACEUTICALS COM 03852X100 4.07 297,330 -39.20 1,441 -10.61 -780 609 37.80
2016-06-30 13F-HR ARALEZ PHARMACEUTICALS COM 03852X100 3.42 488,992 48.91 1,612 38.73 549 -99 -8.51
2016-03-31 13F-HR ARALEZ PHARMACEUTICALS COM 03852X100 328,370 1,162
ARLZ : Aralez Pharmaceuticals Stock Analysis and Research Report

2017-10-23 - Asif

Aralez is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients’ lives while creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas. Its parent corporation, Aralez Pharmaceuticals Inc., was incorporated under the British Columbia Business Corporations Act (“BCBCA”) on December 2, 2015. its global headquarters is located in Mississauga, Ontario, Canada, its U.S. headquarters is located in Princeton, New Jersey, United States, and its Irish headquarters is located in Dublin, Ireland. Aralez was formed for the purpose of facilitating the business combination of POZEN Inc., a Delaware corporation (“Pozen”), and Tribute Pharmaceuticals Canada Inc., a corporation incorporated under the laws of the Province of Ontario, Canada (“Tribute”), which transaction closed on February 5, 2016. On February 5, 2016, pursuant to an Agreement and Plan of Merger and Arr...

Related SEC Filings

ARLZ / Aralez Pharmaceuticals Inc. / Flynn James E - null (Passive Investment)

2018-06-25 sec.gov
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) (62-4)

ARLZ / Aralez Pharmaceuticals Inc. / Flynn James E - null (Passive Investment)

2018-06-25 sec.gov
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) (62-9)

ARLZ / Aralez Pharmaceuticals Inc. / Flynn James E - 3G/A (Passive Investment)

2018-02-14 sec.gov
  SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   SCHEDULE 13G  (Rule 13d-102)   INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)   (Amendment No. 2) *   Aralez Pharmaceuticals, Inc. (Name of Issuer)   Common Shares (Title of Class of Securities)   03852X100 (CUSIP Number)   December 31, 2017  (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the ru (0-2)

ARLZ / Aralez Pharmaceuticals Inc. / Flynn James E - 3G/A (Passive Investment)

2018-02-14 sec.gov
  SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   SCHEDULE 13G  (Rule 13d-102)   INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)   (Amendment No. 2) *   Aralez Pharmaceuticals, Inc. (Name of Issuer)   Common Shares (Title of Class of Securities)   03852X100 (CUSIP Number)   December 31, 2017  (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the ru (0-3)

ARLZ / Aralez Pharmaceuticals Inc. / PAR INVESTMENT PARTNERS LP - SC 13G/A (Passive Investment)

2018-02-15 sec.gov
SC 13G/A     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)*     Aralez Pharmaceuticals Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 03852X100 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☒Rule 13d-1(c) ☐ Rule 13d-1(d)   (0-2)

Related News Stories

Update On Aralez Pharmaceuticals

2018-06-18 seekingalpha
On May 8th Aralez announced it was discontinuing its U.S. operations, slashing costs, selling certain US assets, and focusing on its Cdn.business supported by Vimovo royalties & its Toprol franchise. (62-4)

Aralez Pharmaceuticals: Change In Strategy May Bring A Silver Lining

2018-05-11 seekingalpha
Despite announcing record Q1 2018 revenues, Aralez announced a new strategic direction; discontinuing its U.S. commercial operations; slashing operating expenses to $25MM per annum (from $22MM in Q1 alone). (62-5)

Your Daily Pharma Scoop: Akcea-Ionis Ad Com, Aralez U.S. Shut Down, Lynparza EU Approval

2018-05-09 seekingalpha
Ionis (NASDAQ:IONS) subsidiary Akcea (NASDAQ:AKCA) has an Ad Comm today, May 10, for its volanesoren as an adjunct to diet for the treatment of patients with familial chylomicronemia syndrome. That is a rare disease, and this is an antisense drug. Antisense is Ionis’s contribution, more or less, to medicine. It is a technology, briefly put, where a protein binds to mRNAs and stops them from producing harmful proteins. (409-3)

Helios and Matheson, Gogo Plunge into Tuesday’s 52-Week Low Club

2018-05-08 247wallst
May 8, 2018: Here are four stocks trading with heavy volume among 80 equities making new 52-week lows in Tuesday’s session. On the NYSE advancers led decliners by about 1.04 to 1 and on the Nasdaq, advancers led decliners by about 1.19 to 1. (83-2)

Aralez Pharmaceuticals' (ARLZ) CEO Adrian Adams on Q1 2018 Results - Earnings Call Transcript

2018-05-08 seekingalpha
Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) Q1 2018 Results Earnings Conference Call May 8, 2018 8:00 AM ET (62-0)



CUSIP: 03852X100